OP-101
Phase 2- Indications
- Severe COVID-19, Neuroinflammation
Company intelligence / Profile preview
Orpheris, Inc.
Redwood City, California, United Statesclinicaltrialsarena.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Orpheris has completed Phase 1 studies of OP-101 and enrolled patients in a Phase 2 PRANA clinical study for severe COVID-19. The company received FDA Orphan Drug Designation for OP-101 for childhood cerebral adrenoleukodystrophy (ccALD).
- Therapeutic areas
- PsychiatryRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small molecule drugChemical drugsHydroxyl dendrimer therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Orpheris, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orpheris, Inc..